Browse by author
Lookup NU author(s): Emeritus Professor Jan Scott
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Introduction: Disruptions in sleep and circadian rhythms are observed in individuals with bipolar disorders (BD), both during acute mood episodes and remission. Such abnormalities may relate to dysfunction of the molecular circadian clock and could offer a target for new drugs.Areas covered: This review focuses on clinical, actigraphic, biochemical and genetic biomarkers of BDs, as well as animal and cellular models, and highlights that sleep and circadian rhythm disturbances are closely linked to the susceptibility to BDs and vulnerability to mood relapses. As lithium is likely to act as a synchronizer and stabilizer of circadian rhythms, we will review pharmacogenetic studies testing circadian gene polymorphisms and prophylactic response to lithium. Interventions such as sleep deprivation, light therapy and psychological therapies may also target sleep and circadian disruptions in BDs efficiently for treatment and prevention of bipolar depression.Expert opinion: We suggest that future research should clarify the associations between sleep and circadian rhythm disturbances and alterations of the molecular clock in order to identify critical targets within the circadian pathway. The investigation of such targets using human cellular models or animal models combined with 'omics' approaches are crucial steps for new drug development.
Author(s): Bellivier F, Geoffroy PA, Etain B, Scott J
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Therapeutic Targets
Year: 2015
Volume: 19
Issue: 6
Pages: 747-763
Print publication date: 01/06/2015
Online publication date: 02/03/2015
Acceptance date: 01/01/1900
ISSN (print): 1472-8222
ISSN (electronic): 1744-7631
Publisher: INFORMA HEALTHCARE
URL: http://dx.doi.org/10.1517/14728222.2015.1018822
DOI: 10.1517/14728222.2015.1018822
